TY - JOUR
T1 - ERS statement on respiratory muscle testing at rest and during exercise
AU - Laveneziana, Pierantonio
AU - Albuquerque, Andre
AU - Aliverti, Andrea
AU - Babb, Tony
AU - Barreiro, Esther
AU - Dres, Martin
AU - Dubé, Bruno Pierre
AU - Fauroux, Brigitte
AU - Gea, Joaquim
AU - Guenette, Jordan A.
AU - Hudson, Anna L.
AU - Kabitz, Hans Joachim
AU - Laghi, Franco
AU - Langer, Daniel
AU - Luo, Yuan Ming
AU - Neder, J. Alberto
AU - O'Donnell, Denis
AU - Polkey, Michael I.
AU - Rabinovich, Roberto A.
AU - Rossi, Andrea
AU - Series, Frédéric
AU - Similowski, Thomas
AU - Spengler, Christina
AU - Vogiatzis, Ioannis
AU - Verges, Samuel
N1 - Funding Information:
Maquet, outside the submitted work. B-P. Dubé reports grants and personal fees from Novartis and Roche, personal fees from Boehringer Ingelheim and GSK, outside the submitted work. B. Fauroux has nothing to disclose. J. Gea has nothing to disclose. J.A. Guenette has nothing to disclose. A.L. Hudson reports grants from Lung Foundation Australia and Boehringer Ingelheim, during the conduct of the study; grants from Rebecca L. Cooper Foundation, Lung Foundation Australia, Boehringer Ingelheim, National Health and Medical Research Council (Australia) and University of New South Wales, outside the submitted work. H-J. Kabitz reports personal fees and non-financial support from Inomed Medizintechnik GmbH, non-financial support from nSpire Health GmbH, during the conduct of the study. F. Laghi reports grants from National Institutes of Health, VA Research Service, Liberate Medical LLC and National Science Foundation, outside the submitted work. D. Langer has nothing to disclose. Y-M. Luo has nothing to disclose. J.A. Neder has nothing to disclose. D. O’Donnell reports grants and personal fees from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline, personal fees from Almirall, Novartis and Pfizer, outside the submitted work. M.I. Polkey reports personal and institutional payments for consultancy and speaking from Amicus, Genzyme Sanofi and Biomarin, institutional payments for consultancy from Orion, during the conduct of the study. R.A. Rabinovich has nothing to disclose. A. Rossi has nothing to disclose. F. Series has nothing to disclose. T. Similowski reports personal fees for advisory board work from Pierre Fabre Médicament, during the conduct of the study; personal fees from AstraZeneca, Boehringer Ingelheim France, GSK, Lungpacer Inc., TEVA, Chiesi and Invacare, personal fees and non-financial support from Novartis, outside the submitted work. C. Spengler has nothing to disclose. I. Vogiatzis has nothing to disclose. S. Verges has nothing to disclose.
Publisher Copyright:
© ERS 2019.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Assessing respiratory mechanics and muscle function is critical for both clinical practice and research purposes. Several methodological developments over the past two decades have enhanced our understanding of respiratory muscle function and responses to interventions across the spectrum of health and disease. They are especially useful in diagnosing, phenotyping and assessing treatment efficacy in patients with respiratory symptoms and neuromuscular diseases. Considerable research has been undertaken over the past 17 years, since the publication of the previous American Thoracic Society (ATS)/ European Respiratory Society (ERS) statement on respiratory muscle testing in 2002. Key advances have been made in the field of mechanics of breathing, respiratory muscle neurophysiology (electromyography, electroencephalography and transcranial magnetic stimulation) and on respiratory muscle imaging (ultrasound, optoelectronic plethysmography and structured light plethysmography). Accordingly, this ERS task force reviewed the field of respiratory muscle testing in health and disease, with particular reference to data obtained since the previous ATS/ERS statement. It summarises the most recent scientific and methodological developments regarding respiratory mechanics and respiratory muscle assessment by addressing the validity, precision, reproducibility, prognostic value and responsiveness to interventions of various methods. A particular emphasis is placed on assessment during exercise, which is a useful condition to stress the respiratory system.
AB - Assessing respiratory mechanics and muscle function is critical for both clinical practice and research purposes. Several methodological developments over the past two decades have enhanced our understanding of respiratory muscle function and responses to interventions across the spectrum of health and disease. They are especially useful in diagnosing, phenotyping and assessing treatment efficacy in patients with respiratory symptoms and neuromuscular diseases. Considerable research has been undertaken over the past 17 years, since the publication of the previous American Thoracic Society (ATS)/ European Respiratory Society (ERS) statement on respiratory muscle testing in 2002. Key advances have been made in the field of mechanics of breathing, respiratory muscle neurophysiology (electromyography, electroencephalography and transcranial magnetic stimulation) and on respiratory muscle imaging (ultrasound, optoelectronic plethysmography and structured light plethysmography). Accordingly, this ERS task force reviewed the field of respiratory muscle testing in health and disease, with particular reference to data obtained since the previous ATS/ERS statement. It summarises the most recent scientific and methodological developments regarding respiratory mechanics and respiratory muscle assessment by addressing the validity, precision, reproducibility, prognostic value and responsiveness to interventions of various methods. A particular emphasis is placed on assessment during exercise, which is a useful condition to stress the respiratory system.
UR - http://www.scopus.com/inward/record.url?scp=85059099616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059099616&partnerID=8YFLogxK
U2 - 10.1183/13993003.01214-2018
DO - 10.1183/13993003.01214-2018
M3 - Review article
C2 - 30956204
AN - SCOPUS:85059099616
SN - 0903-1936
VL - 53
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 6
M1 - 1801214
ER -